

Provided by:



## Rheumatology Case Management 2025-2026

**Rheumatology Case Management 2025-2026 - 9/9/2025**

**September 9, 2025**

**9:00 AM - 10:00 AM**

**Online/Rheumatology Conference Room 5 White**

### Target Audience

This program has been designed for ALLERGY AND IMMUNOLOGY, DERMATOLOGY, INTERNAL MEDICINE - Rheumatology, PEDIATRICS - Pediatric Rheumatology

### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss diagnostic skills for rheumatologic diseases.
- 2 Describe common and uncommon manifestations of rheumatologic disease.
- 3 Discuss therapeutic advances and research for treatment of rheumatologic disease.

### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

### Acknowledgement of Commercial Support\*

None

For more information, please contact  
John Davis  
(215) 662-2792  
johdav@upenn.edu

**Check your transcript online at <https://upenn.cloud-cme.com>**

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Michael George, MD	Other Planning Committee Member	Grant or research support-Glaxo Smith Kline Grant or research support-Janssen Pharmaceuticals (J&J) (Relationship has ended) Consulting Fee-Pfizer, Inc. (Relationship has ended) Grant or research support-CSL Behring (Relationship has ended) Grant or research support-Pfizer, Inc. - 06/29/2025
Chadwick R Johr, MD	Other Planning Committee Member	Paid consultant-Bristol-Myers Squibb Consulting Fee-Novartis / Amgen - 07/16/2025
Joshua F. Baker, MD	Other Planning Committee Member	Consulting Fee-CorEvitas LLC Consulting Fee-Formation Bio (Relationship has ended) - 06/26/2025
Sharon Kolasinski, MD	Other Planning Committee Member	Nothing to disclose - 06/27/2025
Steffan Schulz, MD	Other Planning Committee Member	Nothing to disclose - 07/17/2025
Anupama Shahane, MD	Course Director	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astra Zeneca Pharmaceuticals (Relationship has ended) - 06/30/2025
Preethi Thomas, MD	Other Planning Committee Member	Nothing to disclose - 06/27/2025
Peter A Merkel, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc.  Grant or research support-AbbVie, Inc.  Consulting

		Fee-Astra Zeneca Pharmaceuticals  Consulting Fee-Argenx  Grant or research support-Astra Zeneca Pharmaceuticals  Consulting Fee- Boehringer-Ingelheim  Grant or research support-Boehringer-Ingelheim  Consulting Fee-Bristol-Myers Squibb  Grant or research support-Bristol-Myers Squibb  Consulting Fee-Cabaletta (Relationship has ended)  Consulting Fee-CSL Behring (Relationship has ended)  Consulting Fee- Dynacure (Relationship has ended)  Consulting Fee-Genentech (Relationship has ended)  Grant or research support-Genentech (Relationship has ended)  Grant or research support-Eicos (Relationship has ended)  Grant or research support-Electra (Relationship has ended)  Consulting Fee-Sanofi Genzyme (Relationship has ended)  Grant or research support-Sanofi Genzyme (Relationship has ended)  Consulting Fee-Immagene (Relationship has ended)  Consulting Fee- Interius  Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended)  Consulting Fee-Kyverna  Stocks or stock options, excluding diversified mutual funds-Kyverna  Consulting Fee-Lifordi  Stocks or stock options, excluding diversified mutual funds of a publicly traded company- Lifordi  Consulting Fee-Glaxo Smith Kline  Grant or research support-Glaxo Smith Kline  Consulting Fee-Inflarx GMBH (Relationship has ended)  Grant or research support-Inflarx GMBH (Relationship has ended)  Consulting Fee-Magenta (Relationship has ended)  Consulting Fee- Novartis (Advanced Health Media) (Relationship has ended)  Consulting Fee- Neutrolis  Consulting Fee-NS Pharma  Consulting Fee-Quell  Consulting Fee-Takeda Pharmaceuticals  Grant or research support-Takeda Pharmaceuticals  Consulting Fee-Pfizer, Inc. (Relationship has ended)  Consulting Fee- Q32  Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)  Consulting Fee-Sparrow  Consulting Fee-Argenx (Relationship has ended)  Consulting Fee-Visterra  Consulting Fee-Kinevant  Consulting Fee- Sparrow  Consulting Fee-iCell  Royalties or Patent Beneficiary-UpToDate - 06/27/2025
Rennie Rhee, MD	Other Planning Committee Member	Consulting Fee-Novartis (Advanced Health Media) - 06/27/2025
Nora Sandorfi, MD	Other Planning Committee	Consulting Fee-Janssen Pharmaceuticals

	Member	(J&J)   Paid consultant-BMS   Membership on Advisory Committees or Review Panels, Board Membership, etc.- Immunovant   Advisor-Novartis / Amgen - 06/29/2025
Carla Scanzello, MD	Other Planning Committee Member	Nothing to disclose - 06/09/2025
Ethan Craig, MD, MHS	Other Planning Committee Member	Employment-Penn Specialty Pharmacy   Advisor-Penn Home Infusion   Honoraria-Lilly (Relationship has ended)   Consulting Fee-Calico (Relationship has ended)   Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended) - 06/11/2025
Alexis Ogdie, MD, MSPH	Other Planning Committee Member	Consulting Fee-Pfizer, Inc.   Grant or research support-Janssen Pharmaceuticals (J&J)   Consulting Fee-CorEvitas   Grant or research support-AbbVie, Inc.   Grant or research support-Novartis / Amgen   Grant or research support-Pfizer, Inc.   Consulting Fee-Janssen Pharmaceuticals (J&J)   Consulting Fee-Glaxo Smith Kline   Consulting Fee-UCB   Consulting Fee-Bristol-Myers Squibb   Consulting Fee-Novartis / Amgen   Consulting Fee-AbbVie, Inc.   Consulting Fee-Takeda Pharmaceuticals   Ownership-Research Pathfinder - 07/15/2025
Naomi Amudala, CRNP RN	Nurse Planner	Speakers Bureau-Amgen   Paid consultant-Johnson & Johnson - 04/28/2025
Shubhasree Banerjee, MD	Co-Director	Nothing to disclose - 06/27/2025
Chris T Derk, MD	Other Planning Committee Member	Nothing to disclose - 06/27/2025
Jonathan Dunham, MD	Other Planning Committee Member	Nothing to disclose - 06/27/2025
Rachel Dayno, MD	Other Planning Committee Member	Nothing to disclose - 06/30/2025
Kimberly Dequattro, MD	Other Planning Committee Member	Nothing to disclose - 12/02/2024
Ian Cooley, MD	Other Planning Committee Member	Nothing to disclose - 06/27/2025
Meghan J Anderson, DO	Other Planning Committee Member	Nothing to disclose - 06/27/2025
Adrian Alonso, MD	Faculty	Nothing to disclose - 07/29/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected